Literature DB >> 18844597

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Matthew R Olson1, Steven M Varga.   

Abstract

Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants and is an important source of morbidity and mortality in the elderly and immunocompromised. This review will discuss the humoral and cellular adaptive immune responses to RSV infection and how these responses are shaped in the immature immune system of the infant and the aged environment of the elderly. Furthermore, we will provide an overview of our current understanding of the role the various arms of the adaptive immune response play in mediating the delicate balance between the successful elimination of the virus from the host and the induction of immunopathology. Efficacious immunization against RSV remains a high priority within the field and we will highlight recent advances made in vaccine design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844597      PMCID: PMC2630464          DOI: 10.1586/14760584.7.8.1239

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  175 in total

1.  Recombinant Sendai virus for efficient gene transfer to human airway epithelium.

Authors:  Olaf Pinkenburg; Claus Vogelmeier; Sascha Bossow; Wolfgang J Neubert; Raimund B Lutz; Guy Ungerechts; Ulrich M Lauer; Michael Bitzer; Robert Bals
Journal:  Exp Lung Res       Date:  2004-03       Impact factor: 2.459

2.  Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Michael N Teng; Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Authors:  Toru Takimoto; Julia L Hurwitz; Chris Coleclough; Cecilia Prouser; Sateesh Krishnamurthy; Xiaoyan Zhan; Kelli Boyd; Ruth A Scroggs; Brita Brown; Yoshiyuki Nagai; Allen Portner; Karen S Slobod
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease.

Authors:  Guy Tal; Avigdor Mandelberg; Ilan Dalal; Karine Cesar; Eli Somekh; Asher Tal; Anat Oron; Svetlana Itskovich; Ami Ballin; Sion Houri; Avraham Beigelman; Ofer Lider; Gideon Rechavi; Ninette Amariglio
Journal:  J Infect Dis       Date:  2004-05-12       Impact factor: 5.226

5.  Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes.

Authors:  Jojanneke Heidema; Godelieve J de Bree; Patricia M A de Graaff; Wendy W C van Maren; Peter Hoogerhout; Theo A Out; Jan L L Kimpen; Grada M van Bleek
Journal:  J Gen Virol       Date:  2004-08       Impact factor: 3.891

6.  Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Steven M Varga; Thomas J Braciale; Barney S Graham
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Age related differences in humoral immune response to respiratory syncytial virus infection in adults.

Authors:  Edward E Walsh; Ann R Falsey
Journal:  J Med Virol       Date:  2004-06       Impact factor: 2.327

8.  IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.

Authors:  Helene A Haeberle; Antonella Casola; Zoran Gatalica; Sharon Petronella; Hans-Juergen Dieterich; Peter B Ernst; Allan R Brasier; Roberto P Garofalo
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells.

Authors:  Patricia M A de Graaff; Jojanneke Heidema; Martien C Poelen; Mariska E A van Dijk; Michael V Lukens; Sjef P J van Gestel; Judith Reinders; Erik Rozemuller; Marcel Tilanus; Peter Hoogerhout; Cecile A C M van Els; Robbert G van der Most; Jan L L Kimpen; Grada M van Bleek
Journal:  Virology       Date:  2004-09-01       Impact factor: 3.616

10.  Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults.

Authors:  Edward E Walsh; Ann R Falsey
Journal:  J Infect Dis       Date:  2004-06-18       Impact factor: 5.226

View more
  37 in total

1.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

2.  Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Authors:  Naoko Iwata-Yoshikawa; Akihiko Uda; Tadaki Suzuki; Yasuko Tsunetsugu-Yokota; Yuko Sato; Shigeru Morikawa; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa; Noriyo Nagata
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

3.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

4.  The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Yu-Jin Jung; Subbiah Jeeva; Young-Man Kwon; Baik Lin Seong; Sang Moo Kang
Journal:  Antiviral Res       Date:  2019-05-28       Impact factor: 5.970

5.  Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Authors:  Anu Cherukuri; Kathryn Patton; Robert A Gasser; Fengrong Zuo; Jennifer Woo; Mark T Esser; Roderick S Tang
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

6.  Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.

Authors:  Kathryn Patton; Shahin Aslam; Jim Lin; Li Yu; Stacie Lambert; Glenn Dawes; Mark T Esser; Jennifer Woo; Sylvia Janetzki; Anu Cherukuri
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

7.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

8.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

Review 9.  Respiratory viruses and eosinophils: exploring the connections.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Antiviral Res       Date:  2009-04-16       Impact factor: 5.970

Review 10.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.